We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diabetes Resolution and Hormone Changes After BPDLL and LSG

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01481675
First Posted: November 29, 2011
Last Update Posted: November 30, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Theodore K. Alexandrides, University of Patras
  Purpose
To evaluate and compare prospectively the effects of Biliopancreatic Diversion Long Limb (BPDLL) and Laparoscopic Sleeve Gastrectomy (LSG) on resolution of diabetes mellitus type 2.

Condition
Diabetes Mellitus

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Resolution of Diabetes and Hormonal Changes Following Biliopancreatic Diversion Long Limbs and Laparoscopic Sleeve Gastrectomy. A Comparative Prospective Study.

Further study details as provided by Theodore K. Alexandrides, University of Patras:

Primary Outcome Measures:
  • Diabetes resolution at 12 months after surgery [ Time Frame: 12 months after surgery ]

Secondary Outcome Measures:
  • Weight loss at 12 months after surgery [ Time Frame: 12 months after surgery ]
  • Changes of GLP-1 response to glucose [ Time Frame: 12 months after surgery ]
  • Changes in ghrelin levels [ Time Frame: 12 months after surgery ]
  • Changes in PYY response to glucose [ Time Frame: 12 months after surgery ]

Enrollment: 24
Study Start Date: May 2007
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
BPDLL group
Patients subjected to the Biliopancreatic Diversion Long Limbs surgical operation will undergo an oral glucose tolerance preoperatively and 12 months after the operation
LSG group
Patients subjected to laparoscopic sleeve gastrectomy will undergo an oral glucose tolerance test preoperatively and 12 months postoperatively

Detailed Description:
Twelve patients with diabetes mellitus type 2 (DM 2) and body mass index (BMI)> 50kg/m2) will undergo BPDLL and 12 twelve patients with DM 2 and BMI 40-50 kg/m2 will undergo LSG. The patients will be evaluated before and 1, 3 and 12 months after surgery with an oral glucose tolerance test. The investigators aim to investigate the effects of surgery on diabetes resolution, hypertension, dyslipidemia, and also on fasting, and glucose-stimulated insulin, glucagon, ghrelin, peptide-YY and glucagon-like peptide-1 (GLP-1) responses during during an oral glucose tolerance test (OGTT). Resolution of diabetes mellitus will be evaluated according to the criteria of American Diabetes Association with an OGTT. The effects on appetite and satiety will be also evaluated with the use of visual analog scores.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Twelve patients with diabetes mellitus type 2 and BMI> 50kg/m2 will undergo BPDLL and 12 patients with diabetes mellitus type 2 and BMI 40-50kg/m2 will undergo LSG
Criteria

Inclusion Criteria:

  • BMI>50kg/m2 to undergo BPDLL
  • BMI 40-50kg/m2 to undergo LSG
  • Diabetes mellitus type 2

Exclusion Criteria:

  • Chronic medical illness
  • Psychiatric illness
  • Substance abuse
  • Previous gastrointestinal surgery
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01481675


Locations
Greece
University Hospital of Patras
Rion, Achaia, Greece, 26500
University Hospital of Patras
Rion, Achaia, Greece, 26504
Sponsors and Collaborators
University of Patras
Investigators
Principal Investigator: Theodore Alexandrides, Professor University of Patras
Study Director: Fotis Kalfarentzos, Professor University of Patras
  More Information

Responsible Party: Theodore K. Alexandrides, Professor of Medicine, Head of Endocrine Division, University of Patras
ClinicalTrials.gov Identifier: NCT01481675     History of Changes
Other Study ID Numbers: BPDLSG002
BPDLL vs LSG ( Other Identifier: University Hospital of Patras )
First Submitted: November 24, 2011
First Posted: November 29, 2011
Last Update Posted: November 30, 2011
Last Verified: November 2011

Keywords provided by Theodore K. Alexandrides, University of Patras:
biliopancreatic diversion
sleeve gastrectomy
diabetes mellitus
weight loss
ghrelin
PYY
GLP-1

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases